NasdaqGS:REGNBiotechs
Regeneron Pharmaceuticals (REGN) Wins Pasatru Approval, Is The Upside Already Priced In?
Regeneron Pharmaceuticals (REGN) stock moved after the U.S. Food and Drug Administration approved Pasatru for adults with fibrodysplasia ossificans progressiva. This new rare disease therapy is supported by late stage OPTIMA trial data.
See our latest analysis for Regeneron Pharmaceuticals.
The Pasatru approval comes after a strong run in Regeneron Pharmaceuticals’ stock, with a 30.55% 90 day share price return and a 42.21% 1 year total shareholder return, suggesting recent momentum after...